Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label adalimumab dose escalation in Japanese Crohn's disease patients with loss of response
jRCT2080222376Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc. Primary endpoints: Efficacy after adalimumab dose escalation, Safety of adalimumab dose escalation and 1 more.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080222376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222376.